Aurobindo Pharma witnessed a nearly 9% surge in consolidated net profit for Q2FY25, reaching Rs 817 crore. This growth was fueled by an 8% rise in consolidated revenue, driven by a strong performance in formulations, particularly in the US and European markets. However, ARV revenues declined, and API revenues saw a marginal dip.
Related Posts
GST panel puts off call on lower rates for insurance
The GST Council waived taxes on cancer gene therapy and reduced levies on fortified rice kernels. Decisions on ATF inclusion, insurance rates, and food delivery […]
Public holiday: Why RBI has said there will be no trading in government securities, foreign exchange markets, money markets on September 18, 2024
The Reserve Bank of India has stated that trading activities in some financial markets will be halted on September 18, 2024, following a public holiday […]
Post Office Savings Schemes: What are the latest interest rates of Sukanya Samriddhi, PPF, SCSS, NSC & other schemes for July-Sept quarter? Check list
For the July-September 2024 quarter, the government has kept interest rates on post office savings schemes unchanged. Here are the latest interest rates of key […]